Bupropion as a modulator of drug activity
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1. A method of treating major depressive disorder comprising: orally administering a dosage form once a day or twice a day for at least 8 consecutive days, to a human being suffering from major depressive disorder; wherein the dosage form contains, as the only therapeutically active agents in the dosage form, about 90 mg to about 115 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, and about 40 mg to about 70 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan.
2. The method of claim 1 , wherein after orally administering the dosage form, the human being experiences an improvement in a depressive symptom as compared to baseline.
3. The method of claim 1 , wherein orally administering the dosage form is more effective in treating major depressive disorder than orally administering a placebo.
4. The method of claim 1 , wherein orally administering the dosage form is more effective in treating major depressive disorder than orally administering the same amount of the dextromethorphan alone.
5. The method of claim 1 , wherein the dosage form is orally administered twice daily.
6. The method of claim 1 , wherein the dosage form is orally administered for at least 14 consecutive days.
7. The method of claim 1 , wherein the dosage form is orally administered for at least 30 consecutive days.
8. The method of claim 1 , wherein the dosage form has a weight ratio of the dextromethorphan to the bupropion that is about 0.3 to about 0.5.
9. The method of claim 1 , wherein the dosage form is orally administered once a day for 1 day and twice a day thereafter.
10. The method of claim 1 , wherein the dosage form is orally administered once a day for 2 days and twice a day thereafter.
11. The method of claim 1 , wherein the dosage form is orally administered once a day for 3 days and twice a day thereafter.
12. The method of claim 11 , wherein the major depressive disorder is treatment-resistant major depressive disorder.
13. The method of claim 1 , wherein the dosage form is orally administered once a day for 1, 2, 3, 4, 5, 6, or 7 days and twice a day thereafter.
14. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing anxiety.
15. The method of claim 14 , wherein the major depressive disorder is treatment-resistant major depressive disorder.
16. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in improving concentration, reducing mental slowing, or a combination thereof.
17. The method of claim 16 , wherein the major depressive disorder is treatment-resistant major depressive disorder.
18. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in improving mood, reducing feelings of intense sadness, reducing despair, reducing pessimistic worry, or a combination thereof.
19. The method of claim 18 , wherein the major depressive disorder is treatment-resistant major depressive disorder.
20. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing agitation, irritability, restlessness, or a combination thereof.
21. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing guilt, feelings of worthlessness, self-deprecation, or a combination thereof.
22. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing anger, reckless behavior, suicidal thoughts or attempts, or a combination thereof.
23. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing insomnia.
24. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing anorexia, appetite loss, weight loss, or a combination thereof.
25. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing weight gain.
26. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing decreased energy, fatigue, decreased libido, or a combination thereof.
27. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing aches, pains, headaches, cramps, or a combination thereof.
28. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing digestive issues.
29. The method of claim 1 , wherein orally administering the dosage form is more effective than orally administering a placebo in reducing abnormal hormonal circadian rhythms.
30. The method of claim 1 , wherein the dosage form contains about 40 mg to about 50 mg of dextromethorphan hydrobromide and about 100 mg to about 110 mg of bupropion hydrochloride.